Tempest Therapeutics (STU:3OS) ROCE % : -79.60% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tempest Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -79.60%.

Tempest Therapeutics ROCE % Historical Data

The historical data trend for Tempest Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics ROCE % Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-97.79

-75.63

-76.87

-68.27

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial											-84.49	-110.59	-133.82	-96.23	-79.60

Tempest Therapeutics ROCE % Calculation

Tempest Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-25.715	/	( ( (43.508 - 6.869)	+	(47.32 - 8.63) )	/ 2 )
	=	-25.715	/	( (36.639	+	38.69)	/ 2 )
	=	-25.715	/	37.6645
	=	-68.27 %

Tempest Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-27.732	/	( ( (47.32 - 8.63)	+	(40.828 - 9.836) )	/ 2 )
	=	-27.732	/	( ( 38.69	+	30.992 )	/ 2 )
	=	-27.732	/	34.841
	=	-79.60 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Tempest Therapeutics (STU:3OS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tempest Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics (STU:3OS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (STU:3OS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TPST:USA

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Tempest Therapeutics (STU:3OS) Headlines

No Headlines